NIKKEI 225
40,913.65 +332.89 (+0.82%) HANG SENG
18,028.28 +49.71 (+0.28%) CRUDE OIL
84.08 +0.20 (+0.24%) GOLD FUTURES
2,369.40 0.00 (0.00%) DOW
39,308.00 -23.90 (-0.06%) Bitcoin GBP
45,807.15 -1,344.38 (-2.85%)
Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 967.50 |
| Open | 951.10 |
| Bid | 970.00 x 0 |
| Ask | 971.70 x 0 |
| Day's range | 947.50 - 976.20 |
| 52-week range | 504.40 - 1,033.20 |
| Volume | |
| Avg. volume | 2,467,400 |
| Market cap | 4.32T |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 48.67 |
| EPS (TTM) | 19.93 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | 12.80 (1.32%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | 950.04 |
ZacksNVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Investor's Business DailyNovo, Lilly Tumble After Study Ties Blindness Disorder To Weight-Loss Drugs
Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
BenzingaUsing Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
A new observational study has identified a potential link between Novo Nordisk A/S’s (NYSE:NVO) GLP-1 drugs, Ozempic and Wegovy (semaglutide), and a serious eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss. NAION refers to a loss of blood flow to the optic nerve (the cable that connects the eye to the brain). This condition typically causes sudden vision loss in one eye without any pain. Also Read: Joe Biden Suggests Novo Nordisk, Eli
